Alemtuzumab (Campath-1H) Induction in a Pediatric Heart Transplant: Successful Outcome and Rationale for Its Use

Bibhuti Das, Lawrence Shoemaker, Michael Recto, Erle Austin, Robert Dowling

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Despite increasing clinical experience in adult transplantation, induction therapy with alemtuzumab (Campath-1H) has rarely been reported in pediatric solid-organ transplants, and has been limited to kidneys, intestine and multi-visceral organs. Basic science research and clinical observations reported from the adult experience suggest potential benefits of alemtuzumab in pediatric organ recipients. We report successful induction therapy with alemtuzumab and steroid-free maintenance therapy for cardiac transplantation in a teenager, and discuss its merits in this patient.

Original languageEnglish (US)
Pages (from-to)242-244
Number of pages3
JournalJournal of Heart and Lung Transplantation
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Pediatrics
Transplants
Heart Transplantation
Intestines
Therapeutics
Transplantation
Steroids
Kidney
alemtuzumab
Research

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

@article{282e21ba68f0468ca6a9acf375bcfacc,
title = "Alemtuzumab (Campath-1H) Induction in a Pediatric Heart Transplant: Successful Outcome and Rationale for Its Use",
abstract = "Despite increasing clinical experience in adult transplantation, induction therapy with alemtuzumab (Campath-1H) has rarely been reported in pediatric solid-organ transplants, and has been limited to kidneys, intestine and multi-visceral organs. Basic science research and clinical observations reported from the adult experience suggest potential benefits of alemtuzumab in pediatric organ recipients. We report successful induction therapy with alemtuzumab and steroid-free maintenance therapy for cardiac transplantation in a teenager, and discuss its merits in this patient.",
author = "Bibhuti Das and Lawrence Shoemaker and Michael Recto and Erle Austin and Robert Dowling",
year = "2008",
month = "2",
day = "1",
doi = "10.1016/j.healun.2007.11.569",
language = "English (US)",
volume = "27",
pages = "242--244",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "2",

}

Alemtuzumab (Campath-1H) Induction in a Pediatric Heart Transplant : Successful Outcome and Rationale for Its Use. / Das, Bibhuti; Shoemaker, Lawrence; Recto, Michael; Austin, Erle; Dowling, Robert.

In: Journal of Heart and Lung Transplantation, Vol. 27, No. 2, 01.02.2008, p. 242-244.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alemtuzumab (Campath-1H) Induction in a Pediatric Heart Transplant

T2 - Successful Outcome and Rationale for Its Use

AU - Das, Bibhuti

AU - Shoemaker, Lawrence

AU - Recto, Michael

AU - Austin, Erle

AU - Dowling, Robert

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Despite increasing clinical experience in adult transplantation, induction therapy with alemtuzumab (Campath-1H) has rarely been reported in pediatric solid-organ transplants, and has been limited to kidneys, intestine and multi-visceral organs. Basic science research and clinical observations reported from the adult experience suggest potential benefits of alemtuzumab in pediatric organ recipients. We report successful induction therapy with alemtuzumab and steroid-free maintenance therapy for cardiac transplantation in a teenager, and discuss its merits in this patient.

AB - Despite increasing clinical experience in adult transplantation, induction therapy with alemtuzumab (Campath-1H) has rarely been reported in pediatric solid-organ transplants, and has been limited to kidneys, intestine and multi-visceral organs. Basic science research and clinical observations reported from the adult experience suggest potential benefits of alemtuzumab in pediatric organ recipients. We report successful induction therapy with alemtuzumab and steroid-free maintenance therapy for cardiac transplantation in a teenager, and discuss its merits in this patient.

UR - http://www.scopus.com/inward/record.url?scp=38949153071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949153071&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2007.11.569

DO - 10.1016/j.healun.2007.11.569

M3 - Article

C2 - 18267235

AN - SCOPUS:38949153071

VL - 27

SP - 242

EP - 244

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 2

ER -